NYSE:RMD - ResMed Stock Price, News, & Analysis

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed announced a quarterly dividend on Friday, October 26th. Investors of record on Thursday, November 8th will be given a dividend of $0.37 per share on Thursday, December 13th. This represents a $1.48 dividend on an annualized basis and a yield of 1.43%. The ex-dividend date of this dividend is Wednesday, November 7th. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) released its earnings results on Thursday, October, 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.01. The medical equipment provider earned $588.28 million during the quarter, compared to analysts' expectations of $576.66 million. ResMed had a net margin of 13.94% and a return on equity of 26.29%. View ResMed's Earnings History.

ResMed is scheduled to release their next quarterly earnings announcement on Monday, January 28th 2019. View Earnings Estimates for ResMed.

9 analysts have issued 12 month price objectives for ResMed's stock. Their predictions range from $109.00 to $109.00. On average, they anticipate ResMed's share price to reach $109.00 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price. View Analyst Price Targets for ResMed.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed.

Press coverage about RMD stock has been trending negative on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ResMed earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future.

Some companies that are related to ResMed include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Insulet (PODD), Globus Medical (GMED), ICU Medical (ICUI), Integra Lifesciences (IART), Cantel Medical (CMD) and Merit Medical Systems (MMSI).

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.85%), FMR LLC (5.52%), Bank of New York Mellon Corp (1.15%), JPMorgan Chase & Co. (0.94%), Congress Asset Management Co. MA (0.67%) and American Capital Management Inc. (0.45%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

RMD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, West Coast Financial LLC, Congress Asset Management Co. MA, Tandem Investment Advisors Inc., Swiss National Bank, Callahan Advisors LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

RMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., Denali Advisors LLC, Janus Henderson Group PLC, Wells Fargo & Company MN, RPG Investment Advisory LLC and Robeco Institutional Asset Management B.V.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RMD stock can currently be purchased for approximately $103.74.

ResMed has a market capitalization of $15.24 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 5,940 workers across the globe.

The official website for ResMed is http://www.resmed.com.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]